ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

Lancet

Volumn 363, Issue 9403, 2004, Pages 105-111

  Orchard, Jenny A ^a   Ibbotson, Rachel E ^a   Davis, Zadie ^a   Wiestner, Adrian ^b   Rosenwald, Andreas ^b   Thomas, Peter W ^c   Hamblin, Terry J ^a   Staudt, Louis M ^b   Oscier, David G ^a  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; MESSENGER RNA; PROTEIN KINASE ZAP 70;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; HAZARD ASSESSMENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL; T LYMPHOCYTE;

EID: 0347318114     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)15260-9     Document Type: Article

References (30)

1. Kipps T.J. Chronic lymphocytic leukemia. CurrOpin Hematol. 7:2000;223-234.
2. Rozman C., Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 333:1995;1052-1057.
3. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 91:1999;861-868.
4. Byrd J.C., Waselenko J.K., Keating M., Rai K., Grever M.R. Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin Oncol. 27:2000;587-597.
5. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 94:1999;1840-1847.
6. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 94:1999;1848-1854.
7. Krober A., Seiler T., Benner A., et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 100:2002;1410-1416.
8. Oscier D.G., Gardiner A.C., Mould S.J., et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 100:2002;1177-1184.
9. Chevallier P., Penther D., Avet-Loiseau H., et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol. 116:2002;142-150.
10. Lin K., Sherrington P.D., Dennis M., Matrai Z., Cawley J.C., Pettitt A.R. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood. 100:2002;1404-1409.
11. Klein U., Tu Y., Stolovitzky G.A., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 194:2001;1625-1638.
12. Rosenwald A., Alizadeh A.A., Widhopf G., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 194:2001;1639-1647.
13. Wiestner A., Rosenwald A., Barry T.S., et al. ZAP-70 expression identifies a chronic lymphocytic leukemia sub-type with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood. 101:2003;4944-4951.
14. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 87:1996;4990-4997.
15. Hamblin T.J., Orchard J.A., Ibbotson R.E., et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 99:2002;1023-1029.
16. Cook G.P., Tomlinson I.M. The human immunoglobulin VH repertoire. Immunol Today. 16:1995;237-242.
17. Alizadeh A., Eisen M., Davis R.E., et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol. 64:1999;71-78.
18. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:2000;503-511.
19. Armitage P., Berry G. Statistical Methods in Medical Research. 1987;Blackwell Sciences, Oxford.
20. Talbot D., Givan A.L., Shenton B.K., et al. The relevance of a more sensitive crossmatch assay to renal transplantation. Transplantation. 47:1989;552-555.
21. Chan A.C., Iwashima M., Turck C.W., Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell. 71:1992;649-662.
22. Tobin G., Thunberg U., Johnson A., et al. Somatically mutated Ig V(H) 3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 99:2002;2262-2264.
23. Crespo M., Bosch F., Villamor N., et al. ZAP-70 Expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 348:2003;1764-1775.
24. Gurrieri C., McGuire P., Zan H., et al. Chronic lymphocytic leukemia b cells can undergo somatic hypermutation and intraclonal immunoglobulin VHDJH gene diversification. J Exp Med. 196:2003;629-639.
25. Schweighoffer E., Vanes L., Mathiot A., Nakamura T., Tybulewicz V. Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity. 18:2003;523-633.
26. Toyabe S., Watanabe A., Harada W., Karasawa T., Uchiyama M. Specific immunoglobulin E responses in ZAP-70-deficient patients are mediated by Syk-dependent T-cell receptor signalling. Immunology. 103:2001;164-171.
27. Chan A.C., van Oers N.S., Tran A., et al. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol. 152:1994;4758-4766.
28. Kong G.H., Bu J.Y., Kurosaki T., Shaw A.S., Chan A.C. Reconstitution of Syk function by the ZAP-70 protein tyrosine kinase. Immunity. 2:1995;485-492.
29. Chen L., Widhopf G., Huynh L., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 100:2002;4609-4614.
30. Lanham S., Hamblin T., Oscier D., Ibbotson R., Stevenson F., Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 101:2003;1087-1093.